Current status of biomarkers for melanoma metastasis

IDrugs

Volumn 9, Issue 9, 2006, Pages 627-631

  Sondak, Vernon K ^a   Messina, Jane L ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLIN D1; EOSIN; HEMATOXYLIN; INTEGRIN; KI 67 ANTIGEN; MATRIX METALLOPROTEINASE; MYC PROTEIN; NOTCH RECEPTOR; NOTCH2 RECEPTOR; NOTCH3 RECEPTOR; NOTCH4 RECEPTOR; PODOPLANIN; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL XL; PROTEIN MCL 1; STAT3 PROTEIN; SURVIVIN; TISSUE PLASMINOGEN ACTIVATOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

BENIGN TUMOR; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL STUDY; CORRELATION ANALYSIS; DISEASE COURSE; ELASTOSIS; GENE ACTIVATION; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; MELANOMA; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; RELIABILITY; REVIEW; SENTINEL LYMPH NODE BIOPSY; SIGNAL TRANSDUCTION; STANDARDIZATION; SUN EXPOSURE; TUMOR ASSOCIATED LEUKOCYTE; VALIDATION PROCESS;

ANIMALS; BIOLOGICAL MARKERS; HUMANS; MELANOMA; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS;

EID: 33748659489     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. Dalton WS, Friend SH: Cancer biomarkers - an invitation to the table. Science (2006) 312(5777):1165-1168.
2. Basil CF, Zhao Y, Zavaglia K, Jin P, Panelli MC, Voiculescu S, Mandruzzato S, Lee HM, Seliger B, Freedman RS, Taylor PR et al: Common cancer biomarkers. Cancer Res (2006) 66(6):2953-2961.
3. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB et al: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol (2001) 19(16):3622-3634.
4. Sondak VK, Taylor JM, Sabel MS, Wang Y, Lowe L, Grover AC, Chang AE, Yahanda AM, Moon J, Johnson TM: Mitotic rate and younger age are predictors of sentinel lymph node positivity: Lessons learned from the generation of a probabilistic model. Ann Surg Oncol (2004) 11(3):247-258.
5. Tuthill RJ, Unger JM, Liu PY, Flaherty LE, Sondak VK: Risk assessment in localized primary cutaneous melanoma: A Southwest Oncology Group study evaluating nine factors and a test of the Clark logistic regression prediction model. Am J Clin Pathol (2002) 118(4):504-511.
6. Berwick M, Armstrong BK, Ben-Porat L, Fine J, Kricker A, Eberle C, Bamhill R: Sun exposure and mortality from melanoma. J Natl Cancer Inst (2005) 97(3):195-199.
7. Gimotty PA, Van Belle P, Elder DE, Murry T, Montone KT, Xu X, Hotz S, Raines S, Ming ME, Wahl P, Guerry D: Biologic and prognostic significance of dermal Ki-67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol (2005) 23(31):8048-8056.
8. Dadras SS, Lange-Asschenfeldt B, Velasco, P, Nguyen L, Vora A, Muzikansky A, Jahnke K Hauschild A, Hirakawa S, Mihm MC, Detmar M: Tumor lymphangiogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod Pathol (2005) 18(9):1232-1242.
9. Sahni D, Robson A, Orchard G, Szydlo R, Evans AV, Russell-Jones R: The use of LYVE-1 antibody for detecting lymphatic Involvement in patients with malignant melanoma of known sentInel node status. J Clin Pathol (2005) 58(7):715-721.
10. Yu H, Jove R: The STATs of cancer - new molecular targets come of age. Nat Rev Cancer (2004) 4(2):97-105.
11. Nickoloff BJ, Hendrix MJ, Pollock PM, Trent JM, Miele L, Qin JZ: Notch and NOXA-related pathways in melanoma cells. J Invest Dermatol Symp Proc (2005) 10(2):95-104.